HUNTINGTON BEACH, California and AMSTERDAM, Netherlands, September 18 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that its signature breast cancer tumor recurrence test, MammaPrint(R), has been included… more
Source: Agendia Agendia, a world leader in molecular cancer diagnostics, today announced the launch of TargetPrint®, a new diagnostic test that allows physicians to quantitatively determine the gene expression levels of the… more
AMSTERDAM, Netherlands and BARCELONA, Spain, July 15 /PRNewswire/ -- Agendia BV and Ferrer inCode today announced an agreement that will give Ferrer exclusive rights to sell two of Agendia's signature cancer diagnostic… more
AMSTERDAM, The Netherlands, June 19 /PRNewswire/ -- Agendia BV has announced the official opening of the company's new headquarters yesterday at Amsterdam's Science Park at Watergraafsmeer, Kruislaan... more
A prognostic test indicates a patient's risk for another breast cancer tumor after diagnosis and surgical removal of a tumor. The test helps physicians make more personalized treatment decisions for breast cancer… more
By Turna Ray Researchers from Agendia and MD Anderson presented findings at ASCO s annual meeting, suggesting that when used in conjunction with other gene-expression assays, Agendia s MammaPrint, which is indicated… more
Results presented at major U.S. cancer conference CHICAGO, May 30 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of molecular diagnostics, announced today that data from two studies… more
Agendia and Agilent Announce Plans to Jointly Develop New Diagnostic Tests, Extend Supply Agreement (NewsRx.com) -- Agendia BV, a world leader in the rapidly evolving field of molecular diagnostics, and Agilent Technologies,... more
WEDNESDAY, April 23 (HealthDay News) A protein that stops the spread of breast cancer tumors in mice can predict which malignancies might spread, a new study... more
About Agendia